Inmune Bio, Inc. 8-K

What Happened
Inmune Bio, Inc. (INMB) announced on December 22, 2025 (filed in an 8‑K) that it entered into a warrant amendment with certain holders of warrants issued in April 2024. The amendment reduces the exercise price on a total of 1,348,315 outstanding April 2024 warrants to $1.95 (a price above the Minimum Price under Nasdaq Listing Rule 5635(d) as of December 17, 2025) and extends the warrants’ expiration date to June 30, 2026. As consideration for the amendment, holders paid $0.05 per warrant, producing aggregate proceeds to the company of $67,416. The company filed the form of the Warrant Amendment as Exhibit 10.1 to the 8‑K.

Key Details

• Number of warrants amended: 1,348,315 April 2024 warrants.
• New exercise price: $1.95 per warrant (noted as above Nasdaq’s Minimum Price as of 12/17/2025).
• New expiration date: June 30, 2026.
• Consideration paid to company: $0.05 per warrant; total proceeds $67,416.

Why It Matters
This deal can affect potential dilution and timing of capital inflows. Lowering the exercise price and extending the term makes it more likely holders could exercise the warrants before the new June 30, 2026 deadline, which would bring additional capital into the company but could also increase share dilution if exercised. The immediate cash received by Inmune Bio from this amendment is modest ($67k). Investors should note the company complied with Nasdaq pricing rules per the filing.